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Abstract 
Background: Myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS) is a common debilitating disorder 
associated with an intense fatigue, a reduced physical activity, and an impaired quality of life. There are no established 
biological markerof the syndrome. The etiology is unknown and its pathogenesis appears to be multifactorial. Various 
stressors, including intense physical activity, severe infection, and emotional stress are reported in the medical history 
of ME/CFS patients which raises the question whether any physiological and biological abnormalities usually found in 
these patients could be indicative of the etiology and/or the quality-of-life impairment.
Methods: Thirty-six patients and 11 age-matched healthy controls were recruited. The following variables that 
appear to address common symptoms of ME/CFS were studied here: (1) muscle fatigue during exercise has been 
investigated by monitoring the compound muscle action potential (M-wave); (2) the excessive oxidative stress 
response to exercise was measured via two plasma markers (thiobarbituric acid reactive substances: TBARS; reduced 
ascorbic-acid: RAA); (3) a potential inflammatory component was addressed via expression of CD26 on peripheral 
blood mononuclear cells; (4) quality-of-life impairment was assessed using the London Handicap Scale (LHS) and the 
Medical Outcome Study Short Form-36 (SF-36). The medical history of each patient, including the presence of stress-
ors such as intense sports practice, severe acute infection and/or severe emotional stress was documented.
Results: We observed that: (1) there were striking differences between cases and controls with regard to three 
biological variables: post-exercise M-wave, TBARS variations and CD26-expression at rest; (2) each of these three 
variables correlated with the other two; (3) abnormalities in the biomarkers associated with health-related quality of 
life: the LHS score was negatively correlated with the exercise-induced TBARS increase and positively correlated with 
CD26-expression while the pain component of SF-36 was negatively correlated with CD26-expression; (4) the TBARS 
increase and the M-wave decrease were the highest, and the CD26-expression level the lowest in patients who had 
been submitted to infectious stressors.
Conclusion: In ME/CFS patients, severe alterations of the muscle excitability, the redox status, as well as the CD26-
expression level are correlated with a marked impairment of the quality-of-life. They are particularly significant when 
infectious stressors are reported in the medical history.
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Background
As primarily defined by Fukuda [1], and in broad agree-
ment with the latest case definition published in 2015 by 
the Institute of Medicine [2], the myalgic encephalomy-
elitis/chronic fatigue syndrome (ME/CFS) is currently 
described as a debilitating disorder characterized by an 
intense fatigue that is not improved by rest, and that is 
worsened by physical/mental activity. This clinical pic-
ture is usually associated with a marked loss of quality 
of life [1]. The definitions of ME/CFS do not use biologi-
cal markers. Several body systems such as the muscular 
and nervous systems are affected in a context of neuro-
immune alterations and chronic low-grade inflamma-
tion [3–6]. The etiology of ME/CFS is unknown, and its 
pathogenesis appears to be multifactorial, various stress-
ors being repeatedly reported in the medical history of 
these patients, notably an intense sport practice, severe 
infections, and/or emotional stress [7, 8].
Whereas sport practice induces a moderate oxidative 
stress in healthy subjects [9], a strong exercise-induced 
production of reactive oxygen species (ROS) is found in 
ME/CFS patients [10–14]. The antioxidant response is 
also altered at rest, as shown by an increased level of the 
thiobarbituric acid reactive substances (TBARS: a marker 
of lipid peroxidation) and a decreased concentration of 
the reduced ascorbic acid marker (RAA: an endogenous 
antioxidant) [10, 13, 14]. Because the increased ROS 
production affects the muscle excitability [15, 16], the 
increased redox stress in ME/CFS may participate to the 
muscle fatigue as evidenced via an alteration of the com-
pound evoked muscle action potential (M-wave) [10].
The significant dysregulation of the immune system 
found in ME/CFS patients combined increased lev-
els of pro-inflammatory cytokines (e.g. interleukin-1, 
tumor necrosis factor-α), a natural killer cell cytokine 
production and mitogen-activated protein kinase [4–6]. 
A recent work also identified an association of immune 
abnormalities with the severity of ME/CFS symptoms 
and an altered quality of life [17]. These immunological 
abnormalities also involve a decreased expression of the 
T cell activation marker CD26 expressed on peripheral 
blood mononuclear cells (PBMC) [18]. This observa-
tion, together with the reports that CD26-expression is 
increased in patients with fibromyalgia [19] or a meta-
bolic syndrome [20], indicates that CD26-expression 
changes are present in some muscular disorders.
Besides T-cell activation and inflammation control, 
CD26 may also be involved in ME/CFS by its endopro-
teolytic activity that controls the circulating levels of 
various effectors involved in anxiety, chronic pain and 
muscle metabolism. Thus, CD26 can influence the mood, 
pain and muscle components of ME/CFS [21–24]. The 
decrease in CD26-expression in ME/CFS may also be 
associated with an altered redox status [10–14], a rela-
tionship being reported between CD26-expression and 
redox disorders [25, 26].
Seeking help for the diagnosis of ME/CFS, previous 
studies have searched for a correlation between symp-
toms monitored using analogic scales of fatigue and 
markers, in particular, oxidative stress and immune 
markers [17, 27–29]. Other studies reported an alteration 
of the health-related quality-of-life in ME/CFS patients 
but did not examine the relationship with biological 
alterations [30–33].
As indicated above, current case definitions of ME/CFS 
are based on symptoms and do not use biomarkers. This 
raises the question of whether people with ME/CFS share 
any biological abnormalities. If they do the physiologi-
cal and biological abnormalities found in these patients 
could become diagnostic markers.
Methods
Patients
The protocol was approved by the Ethics Committee of 
our institution (CPP Sud Mediterranée 1) and the study 
was carried out by the Code of Ethics of the World Medi-
cal Association (Declaration of Helsinki). The procedures 
have been conducted with the adequate understanding 
and written consent of the subjects (36 ME/CFS patients 
and 11 age-matched healthy controls). ME/CFS patients 
(mean age: 41  ±  6  years; mean weight: 66  ±  3  kg; 22 
females) were recruited during this three-year long study 
(2014–2016) and satisfied the criteria defined by the 
Institute of Medicine of the National Academies [2]: (1) 
severe chronic fatigue for >6 consecutive months (36/36 
cases); (2) a worsening of illness following increases in 
physical or cognitive activity (36/36 cases); (3) impair-
ment of short-term memory or concentration (36/36 
cases), (4) myalgia (24/36 cases); (5) unrefreshing sleep 
(21/36 cases). In most cases, the ME/CFS began suddenly 
(30/36), often with a “flu-like” illness (28/36). Exclusion-
ary diagnoses are the medical and psychiatric causes of 
persistent bodily fatigue.
The data on ME/CFS patients were compared to 
those obtained in an age-matched control group of 11 
healthy volunteers (age: 48 ± 5 years; weight: 71 ± 4 kg; 
6 females; same socio-economic class). They consulted 
for a medical check-up and the medical practitioner 
did not report any symptoms of ME/CFS during the 
interview. The healthy volunteers underwent a system-
atic medical examination, including medical history, 
physical examination, and laboratory testing, which 
revealed no abnormalities. Median values of weight did 
not significantly differ between the ME/CFS and con-
trol groups. The characteristics of the subjects are col-
lected in Table 1.
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Considering their medical history, four groups of 
patients were retrospectively constituted: (1) patients 
reporting an intense sport practice (>6 h/week) (n = 10), 
(2) patients reporting a severe acute infection (perito-
nitis, sepsis, avian influenza…) diagnosed within the 
3–7  month period preceding the onset of ME/CFS, 
(n = 7), (3) patients reporting a severe emotional stress 
(difficult divorce, death of a child…) (n  =  11), or (4) 
patients combining severe infection and emotional stress 
(n = 8).
Psychometrical indices of health‑related quality of life
The ME/CFS health-related quality of life was evaluated 
using two questionnaires: the validated French versions 
of the London Handicap Scale (LHS) [34] as well as the 
Medical Outcome Study Short Form-36 (SF-36) [35], 
this latter being divided into three item groups (physical 
function, bodily pain, and vitality).
Biochemical redox variables
Blood from an antecubital vein was collected on lithium 
heparinate at rest and at the end of the cycling exer-
cise. An aliquot sample was used to measure TBARS 
and reduced ascorbic-acid (RAA) according to meth-
ods previously published [8, 10, 11, 36] and originally 
described by Uchiyama and Mihara [37] and Maickel 
[38], respectively.
CD26 peptidase activity
PBMCs were isolated from the blood using the Vacu-
tainer CPT system (Becton–Dickinson). As previously 
described [19, 23], PBMCs (1.106 cells) were then incu-
bated for 60 min at 37 °C in 75 mM glycine buffer pH 8.7 
with three mM Gly-Pro-p-nitroanilide, a colorimetric 
substrate of the peptidase CD26. The signal background 
was determined by incubation in acetate buffer pH 5, a 
condition in which DPPIV is inactive. Optical density 
values were determined (405 nm).
M‑wave recordings and analyses
As previously reported [10], bipolar (30  mm center-to-
center) Ag–AgCl surface electrodes (Dantec, 13 L 20) 
were used to measure EMG voltage from one rectus femo-
ris muscle. The electrodes were placed between the motor 
point and the proximal tendon. The EMG signal was ampli-
fied (Nihon Kohden, Tokyo, Japan) in the 10–2000  Hz 
range. Compound muscle action potentials (M-waves) 
were evoked in the rectus femoris by direct stimulation 
using a monopolar technique and a constant-current neu-
rostimulator (S88 model Grass, Quincy, MA) that delivered 
supra-maximal shocks with 0.1 ms rectangular pulses. The 
EMG signal was fed to an oscilloscope (model DSO 400, 
Gould), permitting to average M-waves from 8 successive 
potentials and to calculate the peak M-wave amplitude. The 
maximal changes in M-wave amplitude at the end of exer-
cise (ΔM-wave; %) was expressed versus rest value.
Maximal cycling exercise
After a 30-min rest period, each subject performed an 
incremental exercise test on an electrically braked cycle 
ergometer (Ergometrics ER 800, Jaeger) [8, 10, 11, 36]. 
Throughout the incremental exercise trial, the software 
averaged each variable for ten consecutive seconds. The 
maximal VO2 value (VO2max) was measured when the 
subject had reached his/her predicted maximal heart 
rate. M-wave recordings and blood samplings for bio-
chemical analyses were performed at the end of the exer-
cise (VO2max, and at the 5th min post-exercise).
Statistical analysis
Data are presented as mean ±  standard error of means 
(SEM). A two-way ANOVA was performed to compare 
the baseline levels of the biochemical markers between 
ME/CFS patients and controls. The least square regres-
sion analysis was used to compare CD26-expression, 
TBARS (at rest and post-exercise), M-wave amplitude 
variations and LHS/MOS SF-36 data. The significance 
was considered when P < 0.05.
Results
Biochemical variables and muscle excitability at rest and at 
VO2max
Table  1 shows the significant biochemical differences 
observed between ME/CFS patients and controls at rest: 
Table 1 Characteristics, redox status, CD26-expression 
and  muscle fatigue parameters of  ME/CFS patients 
and control subjects
At rest: RAA/TBARS: ratio of antioxidant response (Reduced ascorbic acid, RAA) 
to lipid peroxidation (Thiobarbituric acid reactive substances, TBARS); CD26-
expression measured via DPP-IV activity (AU: arbitrary unit)
Exercise: VO2 max (maximal oxygen uptake); ΔM-wave amplitude: (maximal 
decrease in M-wave amplitude evoked in the rectus femoris); ΔTBARS (maximal 
increase in TBARS post-exercise) (Mean + SEM; * p < 0.05; ** p < 0.01)
ME/CFS (n = 32) Controls (n = 11)
Age (years) 42 ± 7 46 ± 5
Sex ratio (F/M) 24/12 6/5
ME/CFS duration (y) 5 ± 1
At rest
 RAA/TBARS 91 ± 19* 129 ± 15
 CD26-expression (AU) 2.72 + 0.09* 3.60 ± 0.09
End exercise
 VO2max (ml min−1 kg−1) 23 ± 1 26 ± 4
 Δ M-wave (%) −41 ± 8** +8 ± 6
 ΔTBARS (%) +50 ± 10** +15 ± 7
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the RAA/TBARS ratio and the expression of surface 
CD26 per PBMC were lower in the patients.
Exercise-induced changes in M-wave amplitude 
(ΔM-wave) were significantly higher in patients than in 
controls (Table 1). A significant increase in TBARS post-
exercise was found in patients only. Because the duration 
of the exercise test (10–12  min) is well below the time 
needed for the de novo synthesis and cell surface expres-
sion of CD26 [39], we did not examine in all patients 
whether the cycling exercise could affect CD26 expres-
sion (we addressed the situation in 10 patients and did 
not find any differences).
Together, the data obtained at rest and VO2max show 
that the redox status, CD26-expression, and muscle 
excitability were altered in ME/CFS.
When we examined whether these characteristics are 
associated, we found (1) a negative correlation between 
ΔM-wave and ΔTBARS (Fig. 1a), (2) a positive correlation 
between ΔM-wave and CD26-expression (Fig. 1b), and (3) 
a negative correlation between ΔTBARS and CD26-expres-
sion (Fig. 1c). We found no correlation at rest between the 
TBARS level, RAA/TBARS ratio and CD26-expression.
Relationship between biological markers 
and health‑related quality of life
In the patients’ population, the scores of health-related 
quality-of-life were plotted according to the level of 
ΔTBARS or CD26-expression. The LHS score was neg-
atively correlated with ΔTBARS (Fig.  2a) and positively 
correlated with CD26-expression (Fig.  2b). The pain 
component of the SF-36 questionnaire was negatively 
correlated with CD26-expression (Fig. 2c).
Relationship between biological markers and stressors
When the four groups of patients were constituted con-
sidering their medical history, we observed that: (1) the 
M-wave was found to be significantly reduced only when 
both infection and emotional stressors were combined; 
(2) ΔTBARS levels and CD26 expression were markedly 
altered in patients who had a severe infection, regard-
less of the presence of a severe emotional stress; (3) the 
LHS score was markedly low in patients who had a severe 
infection regardless of the presence of a severe emotional 
stress, while the score of the pain component of SF-36 
was high only when both infection and emotional stress-
ors were combined. Figure  3 collects these data. These 
results support the importance of infectious stressors in 
the behavior of the variables we monitored.
Discussion
In ME/CFS patients, we found that (1) the changes in 
the M-wave amplitude post-exercise, the alterations 
of the redox status induced by muscle exercise, and the 
CD26-expression level are correlated; (2) the LHS score 
was correlated to the alterations of the redox status 
induced by exercise and CD26-expression; (3) the pain 
component of MOS SF-36 was correlated to the CD26-
expression level. These variables were mainly altered in 
patients with a history of infectious disease.
The oxidative stress refers to an imbalance in the 
pro- and anti-oxidant status in favour of the former. In 
healthy subjects, this situation is common in skeletal 
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CD26 = 3.170 - (0.004 * ∆TBARS)
r = 0.456; p < 0.01
CD26 = 3.22 - (0.008 * ∆M-wave)
r = 0.592; p < 0.001
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Fig. 1 M-wave, exercise-induced redox stress and CD26-expression. 
Correlation between the decrease in M-wave amplitude post-exercise 
(ΔM-wave) and the maximal increase in TBARS level induced by 
exercise (ΔTBARS) (percent of its resting level; a) Correlation between 
ΔM-wave and CD26-expression at rest (b). Correlation between 
ΔTBARS and CD26-expression at rest (c). Data in ME/CFS patients 
(n = 36) and control healthy subjects (n = 11) are reported. Each 
point could correspond to different individuals. Least square linear 
regression with 95 % confidence intervals is shown
Page 5 of 8Fenouillet et al. J Transl Med  (2016) 14:251 
muscle following exercise because the muscle anti-oxi-
dant defences are weak [9, 36]. In ME/CFS patients, the 
present work and others reported increased levels of 
blood markers of oxidative stress (here, TBARS) and a 
decreased antioxidant defense (here, RAA), a situation 
that promotes an oxidative stress, and eventually affects 
the muscle membrane excitability [10–16]. The correla-
tion found here between the level of oxidative stress and 
the M-wave alteration is consistent with these data.
Our work also reports the correlation of the redox 
markers with the LHS score of quality-of- life. This rela-
tionship is in agreement with studies that examined the 
impact of an altered oxidant-antioxidant status in ME/
CFS and found that the resting blood levels of malon-
dialdehyde [27] and TBARS [28] are associated with 
variations in cognitive symptoms and sleep disturbances 
whereas the total symptom score, joint pain, and postex-
ertional malaise correlate with the isoprostane levels [29].
Regarding CD26, we found that its expression was 
decreased in ME/CFS patients. This observation sup-
ports a previous report [18] but contrasts with a study on 
ME/CFS patients examined after Giardia infection [40]. 
CD26
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Fig. 2 Quality-of-life, exercise-induced redox stress and CD26-expres-
sion. Correlation between the London Handicap Scale (LHS) score 
and ΔTBARS (a) or CD26-expression (b). Correlation between the pain 
component of MOS SF-36 and CD26-expression (c). Only data in ME/
CFS patients (n = 36) are shown. Each point could correspond to 
different individuals. Least square linear regression with 95 % confi-
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Fig. 3 Effects of stressors on M-wave, TBARS level, CD26 expression 
and quality of life scores. Data are represented by box plots with 5th 
and 95th percentiles. Asterisks indicate that values significantly differ 
from those measured in groups of patients with horizontal bar on top 
(*p < 0.05; **p < 0.01; ***p < 0.001)
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The CD26 protease activity controls the circulating level 
of several mediators of pain and mood [21–24]. Because 
mood changes and myalgia often occur in ME/CFS [1, 
2], concentrations of CD26 peptide substrates were 
addressed in patients, and discrepant conclusions were 
reached regarding Neuropeptide Y and Substance-P [41, 
42]. Here, we found that the scores reflecting the quality-
of-life are correlated with CD26-expression. This result 
is in line with the present observations that myalgia was 
often reported by our patients (24/36 patients), impact-
ing their quality-of-life scores. We also observed that the 
CD26 expression level decreased, which may elevate the 
circulating level of pro-nociceptive peptides and promote 
myalgia.
Recently, two studies have investigated the CD26-
expression level in a context of redox alterations. In acute 
lymphoblastic leukemia, the CD26 level is correlated with 
the myeloperoxidase activity, glutathione-s-transferase 
activity and xanthine oxidase activity [25]. Moreover, a 
long term loss of CD26-expression was shown to increase 
the capability to protect against the oxidative stress [26]. 
The low CD26-expression level here reported in ME/
CFS may constitute therefore an adaptive response to 
the chronic redox imbalance found in ME/CFS patients 
[10–14 and the present study], this hypothesis being sup-
ported by the correlation we found between the CD26 
activity and the redox status.
Finally, when patients were sorted according to the 
presence of infection/intense physical activity/emotional 
stress in their medical history, we observed that the sub-
jects who reported episode(s) of severe infection had lev-
els of biomarkers and scores of quality-of-life that were 
more altered compared with those measured in patients 
who did not report severe infections. These results fur-
ther support the role of infectious stressors in ME/CFS 
[7, 8].
We believe that this study has three main limita-
tions: (1) we did not properly quantify the emotional 
stress because only the presence of a major stressful life 
event was considered; (2) in order to address the effect 
of CD26 activity on its peptide substrates, we under-
took to measure the circulating levels of neuropeptide 
Y and substance-P in patients but we did not detect 
correlation with the CD26-expression level, which may 
be explained by the fact that only local concentrations 
of pain and mood mediators act in  vivo,their sam-
pling in  situ being impossible; (3) as in previous ME/
CFS studies [8, 10–14], the finding of an altered redox 
balance in our subjects was only based on measure-
ments of TBARS (which quantifies the level of mem-
brane lipoperoxydes resulting from an excessive ROS 
production) and of the reduced ascorbic acid (a major 
plasma antioxidant). Thus, the effective enhancement 
of intracellular ROS production in ME/CFS cannot be 
evaluated first because it would have required muscle 
biopsies and second because it is counterbalanced by 
the intracellular antioxidants that are not explored in 
the present study.
Conclusion
In accordance with a recent report stating that severe 
ME/CFS patients differover time from moderate ME/CFS 
patients and express significant immune abnormalities 
[17], our results indicate that the simultaneous monitor-
ing of the muscle function, redox response, and CD26-
expression could contribute, together with the health 
status scales, to identifying ME/CFS and to assessing its 
severity. These results may also help to distinguish ME/
CFS from fibromyalgia, because the CD26 activity on 
PBMC increases in fibromyalgia [19] whereas it decreases 
in CFS patients.
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